Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Durect Corp (DRRX) Common Stock USD0.001

Sell:$1.87 Buy:$1.98 Change: $0.05 (2.66%)
NASDAQ:0.37%
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
Sell:$1.87
Buy:$1.98
Change: $0.05 (2.66%)
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
Sell:$1.87
Buy:$1.98
Change: $0.05 (2.66%)
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.

Contact details

Address:
10260 Bubb Rd
CUPERTINO
95014-4166
United States
Telephone:
+1 (408) 7771417
Website:
www.durect.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
DRRX
ISIN:
US2666051048
Market cap:
$375.08 million
Shares in issue:
200.58 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • David Hoffmann
    Independent Chairman of the Board
  • James Brown
    President, Chief Executive Officer and Director
  • Michael Arenberg
    Chief Financial Officer
  • Judy Joice
    Senior Vice President - Operations and Corporate Quality Assurance

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.